CD1c+ and CD141+ myeloid dendritic cells

CD1c+ and CD141+ myeloid dendritic cells is an autologous cell-based immunotherapy developed by Universitair Ziekenhuis Brussel. The therapy consists of two specific subsets of myeloid dendritic cells (myDCs)—CD1c (BDCA-1)+ and CD141 (BDCA-3)+—which are isolated from a patient's peripheral blood via leukapheresis. These cells are administered via intratumoral injection, where they function as professional antigen-presenting cells to prime and activate tumor-specific T-cell responses. By enhancing the recruitment and activation of effector T cells within the tumor microenvironment, the therapy aims to overcome resistance to immune checkpoint inhibitors. It is currently being evaluated in the Phase II LUSCID trial (NCT04571632) in combination with stereotactic body radiation therapy (SBRT), systemic pembrolizumab, and intratumoral avelumab and ipilimumab for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC).

Other names

CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDCautologous myeloid dendritic cellsmyDCCD1c+ myeloid dendritic cells + CD141+ myeloid dendritic cells-Universitair Ziekenhuis Brussel-solid tumors-non-small cell lung cancer